Insulin icodec

Insulin icodec
Clinical data
Pronunciation/ˌɪnsəlɪn ˈaɪkoʊdɛk/
IN-sə-lin EYE-koh-dek
Trade namesAwiqli
AHFS/Drugs.comMonograph
MedlinePlusa626058
Pregnancy
category
  • AU: B3
Routes of
administration
Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
  • (1a-21a),(1b-29b)-Insulin (human), 14a-L-glutamic acid-16b-L-histidine-25b-L-histidine-29b-(N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysine)-
CAS Number
PubChem CID
DrugBank
UNII
ChEMBL
Chemical and physical data
FormulaC280H435N71O87S6
Molar mass6380.33 g·mol−1

Insulin icodec, sold under the brand name Awiqli, is an ultralong-acting basal insulin analogue used in the treatment of diabetes. It is administered by subcutaneous injection once weekly. It was developed by Novo Nordisk.

Insulin icodec was designed to provide basal insulin coverage with once-weekly dosing.

It is approved for medical use in Canada, the European Union, Australia, and in the United States.